Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications for Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (hereafter termed "Fragile X Centers").

In recognition of the rapidly evolving landscape of FMR1-associated research, NIH recently published a new Strategic Plan for Research on FMR1-Associated Conditions.  This Strategic Plan, which was developed in collaboration with many members of the Fragile X community, articulates NIH’s current research priorities, which are directed toward an overarching vision of accelerating the development of effective interventions to prevent or treat FMR1-associated conditions. Successful Fragile X Centers will be composed of multidisciplinary teams of basic, translational and clinical investigators collaborating to address complex, difficult-to-solve problems within specific research priorities identified in the Strategic Plan.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): April 3, 2020

RFA-HD-20-003 Expiration Date April 4, 2020

Agency Website

Eligibility Requirements

Center PD(s)/PI(s) cannot serve as the Lead of a core or research project on another active Fragile X Center.



Amount Description

Applicants may request up to $1.3 million in direct costs per year (excluding subaward F&A costs).

The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

April 3, 2020